17 stories mentioning ITGRUpdated 5d ago
Every FINWIRES story that references ITGR, newest first.
Integer (ITGR) has an average rating of hold and mean price target of $120.60, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Healthcare stocks declined late Monday afternoon, with the NYSE Healthcare Index falling 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Integer (ITGR) agreed to be acquired and taken private by investment firm KKR (KKR) in an all-cash deal with an enterprise value of about $5.7 billion. Integer shares rose 2.6%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a company valued at almost $400 billion, the Financial Times reported Sunday. AstraZeneca shares slumped 6.8%, and Bristol Myers rose 0.4%.Lantheus Holdings (LNTH) agreed to be acquired and taken private by Curium for up to $8 billion. Lantheus shares rose 1.7%.Krystal Biotech (KRYS) shares dropped 8.4% after its Q2 product revenue fell short of analysts' estimates.
Healthcare stocks declined Monday afternoon, with the NYSE Healthcare Index falling 1% and the State Street Health Care Select Sector SPDR ETF (XLV) dropping 0.5%.The iShares Biotechnology ETF (IBB) shed 0.7%.In corporate news, Integer (ITGR) agreed to be acquired and taken private by investment firm KKR (KKR) in an all-cash deal with an enterprise value of about $5.7 billion. Integer shares rose 2.7%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a company valued at almost $400 billion, the Financial Times reported Sunday. AstraZeneca shares slumped 7.5%, and Bristol Myers dropped 0.8%.Lantheus Holdings (LNTH) agreed to be acquired and taken private by Curium for up to $8 billion. Lantheus shares rose 2.2%.
(Updates with latest market prices and developments.)US stocks climbed intraday as oil prices fell after President Donald Trump renewed hopes for a diplomatic breakthrough in the Middle East conflict.The Nasdaq Composite was up 2% at 25,877.1 after midday Monday, while the S&P 500 rose 1.3% to 7,586.4. The Dow Jones Industrial Average climbed 0.9% to 52,962.1. Among sectors, communication services paced the gainers, while energy led the laggards.West Texas Intermediate crude oil tumbled 5.8% to $79.77 a barrel, while Brent dropped 4.8% to $83.70.Over the weekend, Trump said negotiations with Iran would begin Monday, without revealing venue details, news outlets reported. In a social media post, Trump said that he called off a planned attack against Iran because the "perimeters of a deal has been agreed to.""Hopes of a peace deal in the Middle East weighed on crude prices," D.A. Davidson said Monday in a note.However, Iranian Foreign Ministry spokesperson Esmail Baghaei on Monday ruled out an immediate plan to negotiate with Washington, according to news reports. Tehran was in talks with Oman regarding the Strait of Hormuz, the world's most important chokepoint for crude flows, Baghaei reportedly said.Treasury yields were lower intraday, with the 10-year rate down 5.5 basis points at 4.69% and the two-year rate falling 3.1 basis points to 4.26%.In company news, Atkore (ATKR) jumped 28% intraday after the electrical products manufacturer announced a $3.8 billion deal to be acquired by Italian cable maker Prysmian.Lantheus (LNTH) will become a private company following the completion of an up to $8 billion deal with Curium. Lantheus shares were up 2.7% intraday.Integer (ITGR) agreed to be acquired and taken private by investment firm KKR (KKR) in an all-cash deal with an enterprise value of about $5.7 billion. Integer rose 2.7%, while KKR advanced 2.1%.Marriott International (MAR) shares were the worst performer on the S&P 500, down 7.1%. The hotel giant reported second-quarter revenue below Wall Street's estimates amid headwinds related to the Middle East conflict, while it provided a downbeat earnings outlook for the ongoing three-month period.Major companies including SpaceX (SPCX), Eli Lilly (LLY), Advanced Micro Devices (AMD), Caterpillar (CAT), Merck (MRK), McDonald's (MCD), Walt Disney (DIS), Shopify (SHOP) and Uber Technologies (UBER) are slated to release their quarterly results this week.Palantir Technologies (PLTR) is scheduled to release its latest quarterly results after markets close Monday.Spot gold fell 0.2% to $4,038.48 per troy ounce, while silver was up 0.1% at $57.83 per ounce.
Healthcare stocks declined Monday afternoon, with the NYSE Healthcare Index falling 1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.5%.The iShares Biotechnology ETF (IBB) shed 0.5%.In corporate news, Integer (ITGR) has agreed to be acquired and taken private by investment firm KKR (KKR) in an all-cash deal with an enterprise value of about $5.7 billion, the companies said in a joint statement on Monday. Integer shares rose 2.7%.
Integer (ITGR) has an average rating of overweight and mean price target of $110.38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $124.47, Change: $+3.26, Percent Change: +2.69%
Integer (ITGR) has agreed to be acquired and taken private by investment firm KKR (KKR) in an all-cash deal with an enterprise value of about $5.7 billion, the companies said in a joint statement on Monday.Shareholders of Integer will receive $127 per share, a premium of roughly 52% to the medical device manufacturer's share price on April 29, the last trading day before it disclosed a strategic review.Integer serves the cardio and vascular, neuromodulation and cardiac rhythm management markets.Its stock gained 2.7% in most recent premarket activity, while KKR was up 2%.The proposed transaction offers "immediate and certain value" to shareholders, Integer Chief Executive Payman Khales said in the statement.The deal is expected to provide Integer with long-term capital to invest in capacity, technology and innovation, according to the companies."Integer is an exceptional platform with highly differentiated capabilities across a global manufacturing footprint," KKR Partner Max Lin said. "We are excited by the opportunity to deploy capital and resources to further advance Integer's next chapter of growth and innovation."The transaction, which requires approval from Integer's shareholders and clearance from regulators, is expected to complete by the end of the year. Following completion, Integer's shares will no longer trade publicly.Separately, Integer reported second-quarter adjusted earnings of $1.60 per share, up from $1.55 a year earlier, ahead of the FactSet-polled consensus of $1.38. Sales declined 2.6% to $464.1 million, but came in higher than the Street's view for $450.7 million.The company withdrew its outlook in light of its proposed acquisition by KKR.
Integer Holdings (ITGR) has an average rating of overweight and mean price target of $110.38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Healthcare stocks were rising pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.2% higher and the iShares Biotechnology ETF (IBB) advancing by 0.8%.AstraZeneca (AZN) is in talks with Bristol Myers Squibb (BMY) about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, the Financial Times reported, citing unnamed people familiar with the matter. Astrazeneca stock was 7% lower, while Bristol Myers Squibb shares were up more than 3% premarket.Supernus Pharmaceuticals (SUPN) and Indivior Pharmaceuticals (INDV) said they will merge in a tax-free, all-stock deal. Shares of Supernus Pharmaceuticals were up more than 14% and Indivior Pharmaceuticals stock advanced past 1% pre-bell.KKR (KKR) entered into a definitive agreement to acquire Integer (ITGR) through affiliated funds in an all-cash transaction at an enterprise value of $5.7 billion, the companies said. Integer shares were up more than 2% premarket.
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5%, and the actively traded Invesco QQQ Trust (QQQ) was 0.2% higher in Monday's premarket activity as traders hope for a US-Iran truce.US stock futures were higher, with S&P 500 Index futures up 0.5%, Dow Jones Industrial Average futures advancing 0.9%, and Nasdaq futures gaining 0.3% before the start of regular trading.July's manufacturing data from S&P Global will be released at 9:45 am ET.The ISM's manufacturing report and June's construction data will be released at 10 am ET.In premarket activity, bitcoin was down by 1.4%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 0.8% lower, Ether ETF (EETH) retreated 1.7%, and Bitcoin & Ether Market Cap Weight ETF (BETH) declined 0.1%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.8%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was down 0.2%, and the iShares US Consumer Staples ETF (IYK) was 0.9% lower. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increased 1.1%. The VanEck Retail ETF (RTH) and the State Street SPDR S&P Retail ETF (XRT) were inactive.Alibaba (BABA) shares were up more than 4% pre-bell after the company said in a social media post that it launched Qwen3.8-Max, its latest large language model, and plans to release the model's open weights next week alongside Qwen3.8-27B.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 1.1%, the Vanguard Health Care Index Fund (VHT) was up 0.8%, while the iShares US Healthcare ETF (IYH) increased 0.04%. The iShares Biotechnology ETF (IBB) was 0.4% higher.AstraZeneca (AZN) stock was down more than 4% premarket, while Bristol Myers Squibb (BMY) gained 4% after Financial Times reported Sunday that the companies are in talks about a potential combination that would create a pharmaceutical company valued at nearly $400 billion.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 0.5%, the iShares US Technology ETF (IYW) was flat, and the iShares Expanded Tech Sector ETF (IGM) was up 0.1%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was 1.5% lower, while the iShares Semiconductor ETF (SOXX) fell by 2.4%.Parsons (PSN) shares were up more than 2% in premarket activity after the company said it will serve as the lead designer for the Interstate 526 Long Point Road Interchange Improvements project in South Carolina.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.8%. Direxion Daily Financial Bull 3X Shares (FAS) was up 2.3%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 2.3% lower.KKR (KKR) shares were up more than 1% in early hours activity after the company entered into a definitive agreement to acquire Integer (ITGR) through affiliated funds in an all-cash transaction at an enterprise value of $5.70 billion. Integer stock was 2.6% higher.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.6%, while the Vanguard Industrials Index Fund (VIS) was up 0.6% and the iShares US Industrials ETF (IYJ) was 0.4% higher.Boeing (BA) stock was up more than 1% before the opening bell after the company said it has delivered Somon Air's first 737 Max aircraft.EnergyThe iShares US Energy ETF (IYE) was inactive, while the State Street Energy Select Sector SPDR ETF (XLE) was down by 1.2%.Shell (SHEL) stock was down more than 1% before market open after the company agreed to sell its European onshore renewables portfolio to TotalEnergies (TTE). TotalEnergies' shares were 0.6% lower.CommoditiesFront-month US West Texas Intermediate crude oil fell by 6.8% to $78.92 per barrel on the New York Mercantile Exchange. Natural gas was up 0.8% at $2.77 per 1 million British Thermal Units. The United States Oil Fund (USO) decreased by 6.8%, while the United States Natural Gas Fund (UNG) was 0.5% higher.Gold futures for November advanced by 0.2% to $4,114.80 an ounce on the Comex. Silver futures gained by 0.7% to reach $58.18 an ounce. SPDR Gold Shares (GLD) was up by 0.1%, and the iShares Silver Trust (SLV) fell by 0.4%.
(Updates to add KKR's response in the fourth paragraph.)KKR (KKR) is nearing a deal to acquire Integer (ITGR), valuing the medical-device outsourcing company at about $127 a share, The Wall Street Journal reported Friday, citing people familiar with the matter.The deal could be announced as soon as next week, the report said, adding that there are no guarantees that a deal will materialize.Shares of Integer were up 20.2% in Friday trading.A spokesperson for KKR declined to comment, while Integer did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $101.52, Change: $+0.54, Percent Change: +0.53%
KKR (KKR) is nearing a deal to acquire Integer (ITGR), valuing the medical-device outsourcing company at about $127 a share, The Wall Street Journal reported Friday, citing people familiar with the matter.The deal could be announced as soon as next week, the report said, adding that there are no guarantees that a deal will materialize.Shares of Integer were up 20.2% in Friday trading.KKR and Integer did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $100.90, Change: $-0.09, Percent Change: -0.08%
Integer's (ITGR) ongoing strategic review process and private equity interest in the contract manufacturing organization sector combined with the 2025-end stock selloff suggests limited downside to numbers, Oppenheimer said in a Wednesday research report.The macro environment remains uncertain and dislocations canhappen fast, while private credit exposure for PE funds remains a concern as well, analysts wrote.Integer's broad base of blue-chip clients, where 70% of contracts being long-term in nature, provide the company story with automatic "buffers" for risk mitigation, according to the note.The brokerage said it upgraded the stock to outperform from perform with a price target of $115 per share.Price: $90.99, Change: $+6.01, Percent Change: +7.07%
Integer Holdings (ITGR) has an average rating of overweight and mean price target of $97.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target to $90 from $97, on a forward P/E of 13.7x our 2027 EPS, below ITGR's 10-year historical forward average of 17.6x. We cut our 2026 EPS view to $6.16 from $6.74 as we expect some margin pressures ahead, and decrease 2027 to $6.57 from $6.88. Adj. operating margin was -230 bps Y/Y to 13.9% in Q1, primarily due to lower fixed cost absorption from reduced sales volumes. ITGR's Q1 results came in line with previous guidance, with adj. EPS of $1.20 and revenue of $440M. Yet, ITGR significantly lowered its full-year 2026 outlook, citing recent forecast reductions from customers, primarily in the electrophysiology market, and additional risk adjustments made across the portfolio. The new guidance projects a Y/Y reported sales decline of 1%-3% and lowered adj. EPS of $5.83-$6.40. Given these challenges, we think the announced strategic review could be timely as ITGR aims to explore opportunities to maximize shareholder value, including a potential transaction or continuing its stand-alone strategy.
(Updates with recent stock movement and announcement of a strategic review in the headline, first paragraph, and eighth paragraph.)Integer (ITGR) shares were up 5.2% in afternoon trading on Thursday after reporting fiscal Q1 results that beat analysts' expectations and announcing its board has initiated a strategic review.The company reported fiscal Q1 adjusted earnings of $1.20 per diluted share, compared with $1.31 a year earlier.Analysts surveyed by FactSet expected $1.19.Sales for the quarter ended April 3 were $439.6 million, compared with $437.4 million a year earlier.Analysts surveyed by FactSet expected $426.5 million.The company said it now expects fiscal 2026 adjusted diluted EPS of $5.83 to $6.40, compared with previous outlook range of $6.29 to $6.78. Analysts surveyed by FactSet expect $6.49.Full-year sales are now projected to be in the range of $1.81 billion to $1.84 billion, down from $1.83 billion to $1.88 billion previously. Analysts surveyed by FactSet expect $1.85 billion.Integer said it did not set a deadline for completing the review of potential opportunities, including a sale, merger, or business combination.Price: $88.00, Change: $+4.33, Percent Change: +5.18%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Integer Holdings delivered Q1 2026 results that slightly beat expectations, with sales of $440M up 0.5% Y/Y, $14M above expectations. GAAP EPS improved to $0.48 vs. -$0.66 prior year, though adjusted EPS declined 8.4% to $1.20 and adjusted EBITDA fell 7%, reflecting underlying operational pressure. The most significant development was Integer's announcement of a strategic review process, in our view, with the Board exploring options including potential sale, merger, or strategic business combination. Management's risk-adjusted 2026 outlook with sales guidance of $1,805M-$1,835M implies a -3% to -1% Y/Y decline and adjusted EPS of $5.83-$6.40 (-9% to 0% Y/Y). Segment performance remained uneven, with CRM & Neuromodulation showing resilience at +5% Y/Y while C&V managed only 1% growth. In our view, the strategic review suggests the Board is evaluating whether standalone execution can deliver optimal shareholder value amid execution challenges.
